Transforming Growth Factor‐β Modulates Cancer Stem Cell Traits on CD44 Subpopulations in Hepatocellular Carcinoma
Journal of Cellular Biochemistry · 2025
DOI: 10.1002/jcb.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2025. Verfasst von Mario Alejandro Aguilar-Chaparro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), México City, México. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Neoplastic Stem Cells, Liver Neoplasms, Transforming Growth Factor beta. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a formidable malignancy, with growing interest in identifying cancer stem cells (CSCs) as potential therapeutic targets. CD44 isoforms have emerged as promising CSC markers in HCC, often associated with epithelial‐mesenchymal transition (EMT) induced by transforming growth factor‐beta (TGF‐β). However, the intricate relationship between CSC traits, CD44 isoforms, and TGF‐β effects on CD44 subpopulations in HCC remains unclear. This study aimed to clarify how TGF‐β influences proteomic changes and CSC traits in subpopulations expressing standard CD44 isoform (CD44std) and CD44 variant 9 (CD44v9). Treating SNU‐423 cells with TGF‐β lead to notable morphological changes, resembling a spindle‐like phenotype, along with reductions in CD44v9+ subpopulations and differential CD44std expression. Proteomic analysis highlighted significant alterations in signaling pathways, particularly the mitogen‐activated protein kinase (MAPK) pathway. Validation experiments demonstrated upregulation in CD44std cells and downregulation in CD44v9 cells post‐TGF‐β treatment. Furthermore, TGF‐β exerted regulatory influence over Sox2 and Nanog expression, resulting in increased colony and spheroid formation in CD44std cells but decreased capabilities in CD44v9 cells. TGF‐β also enhanced the migratory and invasive properties of both subpopulations through EMT, alongside increased adhesive abilities in CD44v9 cells. These findings illuminate the dynamic interplay between TGF‐β and CD44std/CD44v9 subpopulations, emphasizing the role of MAPK signaling and modulation of CSC traits. This research contributes to understanding the dynamic interplay between CD44 isoforms and TGF‐β in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), México City, México.
- Laboratorios Nacionales de Servicios Experimentales, Centro de Investigación y Estudios Avanzados del IPN, Ciudad de México, México.
- CONAHCyT- Universidad Autónoma de Guerrero, Chilpancingo, México.
ORCID-Profile: Mario Alejandro Aguilar-Chaparro
Zitieren
APA
Aguilar-Chaparro, M. A., Rivera-Pineda, S. A., Hernández-Galdámez, H. V., Ríos-Castro, E., Garibay-Cerdenares, O. L., Piña-Vázquez, C., & Villa-Treviño, S. (2025). Transforming Growth Factor‐β Modulates Cancer Stem Cell Traits on CD44 Subpopulations in Hepatocellular Carcinoma. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.70003
Vancouver
Aguilar-Chaparro MA, Rivera-Pineda SA, Hernández-Galdámez HV, Ríos-Castro E, Garibay-Cerdenares OL, Piña-Vázquez C, et al. Transforming Growth Factor‐β Modulates Cancer Stem Cell Traits on CD44 Subpopulations in Hepatocellular Carcinoma. Journal of Cellular Biochemistry. 2025. doi:10.1002/jcb.70003
BibTeX
@article{AguilarChaparro2025,
author = {Aguilar-Chaparro, Mario Alejandro and Rivera-Pineda, Sonia Andrea and Hernández-Galdámez, Hury Viridiana and Ríos-Castro, Emmanuel and Garibay-Cerdenares, Olga Lilia and Piña-Vázquez, Carolina and Villa-Treviño, Saúl},
title = {Transforming Growth Factor‐β Modulates Cancer Stem Cell Traits on CD44 Subpopulations in Hepatocellular Carcinoma},
journal = {Journal of Cellular Biochemistry},
year = {2025},
doi = {10.1002/jcb.70003}
}
EUVIMED